Drug Discovery Today: Technologies最新文献

Localization of Organelle Proteins by Isotope Tagging: Current status and potential applications in drug discovery research 同位素标记在细胞器蛋白定位中的应用现状及在药物发现研究中的潜在应用

Drug Discovery Today: Technologies Pub Date : 2021-12-01 DOI: 10.1016/j.ddtec.2021.06.003

Mohamed A.W. Elzek , Josie A. Christopher , Lisa M. Breckels , Kathryn S. Lilley

引用次数: 4

Editorial for the role(s) of MS in drug research and development MS在药物研究和开发中的作用

Drug Discovery Today: Technologies Pub Date : 2021-12-01 DOI: 10.1016/j.ddtec.2021.10.007

Maarten Honing

引用次数: 0

Progress in Free Energy Perturbation: Options for Evolving Fragments 自由能摄动的进展:演化碎片的选择

Drug Discovery Today: Technologies Pub Date : 2021-12-01 DOI: 10.1016/j.ddtec.2021.10.001

Lorena Zara, Nina-Louisa Efrém, Jacqueline E. van Muijlwijk-Koezen, Iwan J.P. de Esch, Barbara Zarzycka

引用次数: 6

A technical overview of supercritical fluid chromatography-mass spectrometry (SFC-MS) and its recent applications in pharmaceutical research and development 超临界流体色谱-质谱(SFC-MS)技术综述及其在药物研发中的最新应用

Drug Discovery Today: Technologies Pub Date : 2021-12-01 DOI: 10.1016/j.ddtec.2021.10.002

Liuxi Chen, Brian Dean, Xiaorong Liang

引用次数: 6

Application of proteomics to understand maturation of drug metabolizing enzymes and transporters for the optimization of pediatric drug therapy 应用蛋白质组学了解药物代谢酶和转运体的成熟，以优化儿科药物治疗

Drug Discovery Today: Technologies Pub Date : 2021-12-01 DOI: 10.1016/j.ddtec.2021.06.008

Eva J. Streekstra , Frans G.M. Russel , Evita van de Steeg , Saskia N. de Wildt

{"title":"Application of proteomics to understand maturation of drug metabolizing enzymes and transporters for the optimization of pediatric drug therapy","authors":"Eva J. Streekstra , Frans G.M. Russel , Evita van de Steeg , Saskia N. de Wildt","doi":"10.1016/j.ddtec.2021.06.008","DOIUrl":"10.1016/j.ddtec.2021.06.008","url":null,"abstract":"<div><p>Drug disposition in children is different compared to adults. Growth and developmental change the processes involved in drug disposition and efficacy, including membrane transporters and drug metabolizing enzymes, but for many of these proteins, the exact changes have not been fully elucidated to date. Quantitative proteomics offers a solution to analyze many DME and DT proteins at once and can be performed with very small tissue samples, overcoming many of the challenges previously limiting research in this pediatric field. Liquid chromatography tandem mass spectrometry (LC–MS/MS) based methods for quantification of (membrane) proteins has evolved as a golden standard for proteomic analysis. The last years, big steps have been made in maturation studies of hepatic and renal drug transporters and drug metabolizing enzymes using this method. Protein and organ specific maturation patterns have been identified for the human liver and kidney, which aids pharmacological modelling and predicting drug dosing in the pediatric population. Further research should focus on other organs, like intestine and brain, as well as on innovative methods in which proteomics can be used to further overcome the limited access to pediatric tissues, including liquid biopsies and organoids. In this review there is aimed to provide an overview of available human pediatric proteomics data, discuss its challenges and provide guidance for future research.</p></div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2021.06.008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39586736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

MALDI mass Spectrometry based proteomics for drug discovery & development 基于MALDI质谱的蛋白质组学用于药物发现和开发

Drug Discovery Today: Technologies Pub Date : 2021-12-01 DOI: 10.1016/j.ddtec.2021.09.002

Faizan Zubair

引用次数: 2

Fragment-to-lead tailored in silico design 碎片到铅定制的硅设计

Drug Discovery Today: Technologies Pub Date : 2021-12-01 DOI: 10.1016/j.ddtec.2021.08.005

Moira Rachman , Serena Piticchio , Maciej Majewski , Xavier Barril

{"title":"Fragment-to-lead tailored in silico design","authors":"Moira Rachman , Serena Piticchio , Maciej Majewski , Xavier Barril","doi":"10.1016/j.ddtec.2021.08.005","DOIUrl":"10.1016/j.ddtec.2021.08.005","url":null,"abstract":"<div><p><span>Fragment-based drug discovery (FBDD) emerged as a disruptive technology and became established during the last two decades. Its rationality and low entry costs make it appealing, and the numerous examples of approved drugs discovered through FBDD validate the approach. However, FBDD still faces numerous challenges. Perhaps the most important one is the transformation of the initial fragment hits into viable leads. Fragment-to-lead (F2L) optimization is resource-intensive and is therefore limited in the possibilities that can be actively pursued. </span><em>In silico</em> strategies play an important role in F2L, as they can perform a deeper exploration of chemical space, prioritize molecules with high probabilities of being active and generate non-obvious ideas. Here we provide a critical overview of current <em>in silico</em> strategies in F2L optimization and highlight their remarkable impact. While very effective, most solutions are target- or fragment- specific. We propose that fully integrated <em>in silico</em> strategies, capable of automatically and systematically exploring the fast-growing available chemical space can have a significant impact on accelerating the release of fragment originated drugs.</p></div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2021.08.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39732466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Editorial to technologies in fragment-based drug discovery 编辑基于片段的药物发现技术

Drug Discovery Today: Technologies Pub Date : 2021-12-01 DOI: 10.1016/j.ddtec.2021.09.001

Iwan J.P. De Esch

引用次数: 0

Structure-driven approaches and technologies for drug discovery 结构驱动的药物发现方法和技术

Drug Discovery Today: Technologies Pub Date : 2021-12-01 DOI: 10.1016/j.ddtec.2021.11.001

André Richters, Sven Hennig

引用次数: 0

Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches 利用计算机药物再利用方法开发SARS-CoV-2治疗方法的蛋白质组学进展

Drug Discovery Today: Technologies Pub Date : 2021-12-01 DOI: 10.1016/j.ddtec.2021.06.004

Amrita Mukherjee , Ayushi Verma , Surbhi Bihani, Ananya Burli, Krishi Mantri, Sanjeeva Srivastava

{"title":"Proteomics advances towards developing SARS-CoV-2 therapeutics using in silico drug repurposing approaches","authors":"Amrita Mukherjee , Ayushi Verma , Surbhi Bihani, Ananya Burli, Krishi Mantri, Sanjeeva Srivastava","doi":"10.1016/j.ddtec.2021.06.004","DOIUrl":"10.1016/j.ddtec.2021.06.004","url":null,"abstract":"<div><p>Standing amidst the COVID-19 pandemic, we have faced major medical and economic crisis in recent times which remains to be an unresolved issue till date. Although the scientific community has made significant progress towards diagnosis and understanding the disease; however, effective therapeutics are still lacking. Several omics-based studies, especially proteomics and interactomics, have contributed significantly in terms of identifying biomarker panels that can potentially be used for the disease prognosis. This has also paved the way to identify the targets for drug repurposing as a therapeutic alternative. US Food and Drug Administration (FDA) has set in motion more than 500 drug development programs on an emergency basis, most of them are focusing on repurposed drugs. Remdesivir is one such success of a robust and quick drug repurposing approach. The advancements in omics-based technologies has allowed to explore altered host proteins, which were earlier restricted to only SARS-CoV-2 protein signatures. In this article, we have reviewed major contributions of proteomics and interactomics techniques towards identifying therapeutic targets for COVID-19. Furthermore, <em>in-silico</em> molecular docking approaches to streamline potential drug candidates are also discussed.</p></div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2021.06.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10383449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4